After-Hours Stock Movers:

Surface Oncology (Nasdaq: SURF) 14.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for one of the company’s lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.

9 Meters Biopharma, Inc. (NASDAQ: NMTR) 11.8% LOWER; commenced a proposed underwritten public offering of shares of its common stock.

CASI Pharma (NASDAQ: CASI) 10% HIGHER; CEO, Wei-Wu He, disclosed the purchase of 3 million shares on 03/26 at $2.05.

Chewy (NYSE: CHWY) 9.4% HIGHER; reported Q4 revenue of $2.04 billion versus the consensus estimate of $1.96 billion.

Lineage Cell Therapeutics Inc. (NYSE: LCTX) 8.9% HIGHER; Cantor Fitzgerald initiates coverage with an Overweight rating and a price target of $6.00.

Equillium, Inc. (Nasdaq: EQ) 7.4% HIGHER; announced favorable topline data from the Type A group of the EQUALISE study in patients with systemic lupus erythematosus (SLE). In this study, itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated. In addition, itolizumab demonstrated a dose-dependent reduction of cell surface CD6 expression on effector T cells, a leading indicator of drug activity, consistent with its mechanism of action.

Cleveland-Cliffs (NYSE: CLF) 7.2% HIGHER; sees Q1 2021 adjusted EBITDA of approximately $500 million.

SQZ Biotechnologies (NYSE: SQZ) 4.8% HIGHER; Brookline initiates coverage with a Buy rating and a price target of $40.00.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) 3.7% LOWER; Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively

BlackBerry (NYSE: BB) 3.4% LOWER; reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $215 million versus the consensus estimate of $246.36 million.

ProQR Therapeutics N.V. (Nasdaq: PRQR) 3.2% LOWER; announced that it intends to offer and sell its ordinary shares in an underwritten public offering